Navigation Links
Drug Holds Promise Against AIDS
Date:7/24/2008

Medication helps those with HIV who become treatment-resistant, study shows

THURSDAY, July 24 (HealthDay News) -- New research offers more evidence that a new AIDS drug brings significant benefits to patients who have failed other treatments.

The drug, known as raltegravir (Isentress), almost doubles the likelihood that patients will beat back the AIDS virus despite being immune to other medications, according to a study in the July 24 issue of the New England Journal of Medicine.

"We now have a drug that can bring many people back from a downward curve with no hope for resurrection of the immune system and no hope for control of the virus," said study author Dr. Roy Steigbigel, head of the HIV Center at Stony Brook University.

The federal government has already approved raltegravir for use in so-called "salvage therapy," based on early findings from this study. But the completed research -- funded by Merck & Co., the drug's manufacturer -- shows that the raltegravir continues to work over time, Steigbigel said.

While AIDS has become much more treatable over the past 12 years, thanks to a new generation of drugs, some patients continue to develop resistance to medications. Despite the medical advances, the AIDS virus in the body can learn to evolve into new forms that aren't susceptible to the killing power of drugs.

Patients who don't follow their drug regimens to the letter are most likely to become immune to the drugs, but even the most careful patients can develop resistance, Steigbigel said.

To complicate matters, some patients are immune to drugs, because they were infected by someone with a resistant strain of the AIDS virus.

Raltegravir is unique, because it's part of a new class of AIDS drugs, meaning the virus hasn't encountered it before. "There aren't going to be viruses out there that are resistant to this," Steigbigel said. "That's why it's considered somewhat of a breakthrough."

In the new study, AIDS patients randomly received either raltegravir or a placebo. The patients all received doses of other drugs that are routinely prescribed to help patients in their conditions.

At the 16th week of the study, 62 percent of 458 patients who took raltegravir saw their HIV levels drop to a low level -- below 50 copies per milliliter. Only 35 percent of those who took the placebo saw their levels go that low.

The levels remained consistent when patients were tested at the 48th week. As for side effects, there were about as many among both groups.

Rowena Johnston, vice president of research for The Foundation for AIDS Research, said the development of better treatments for drug-resistant AIDS patients is crucial.

"Rates of drug resistance have increased steadily in the developed world because of the difficulties associated with adhering to treatment regimens," she said. "This problem will surely be multiplied several-fold as patients in the developing world are exposed to antiretroviral therapy for increasing lengths of time."

More information

Learn more about raltegravir from aidsinfonet.org.



SOURCES: Roy Steigbigel, M.D., professor, medicine, and chief, HIV Center, Stony Brook University, N.Y.; Rowena Johnston, Ph.D., vice president, research, Foundation for AIDS Research, New York City; July 24, 2008, New England Journal of Medicine


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Blue Cross and Blue Shield Association Holds Forum to Explore Patient Safety and Healthcare Quality Initiatives
2. Fauquier Health System Holds a Food Show with a Twist Long Term Care Patients Hold the Judges Pen as Vendors Vie for Approval
3. Discovery of widespread tumor growth gene holds promise for effective anti-cancer treatment
4. Epilepsy Drug Holds Promise as Treatment for Alcoholism
5. Sunday, October 14, MSPP holds Sixth Annual Lucero Memorial Run and Latino Leadership Breakfast
6. Alzheimers Foundation of America Holds Fifth Annual National Memory Screening Day
7. European Patent Office Upholds Verathons IP Against Aircraft Medical Challenge
8. University Hospitals Case Medical Center finds new treatment holds promise for Tourette syndrome
9. Go Red For Women Holds Nationwide Casting Call to Find the Heart of Go Red
10. Fruit fly phlebotomy holds neuroscience promise
11. American Association for Dental Research holds 37th annual meeting
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Holds Promise Against AIDS
(Date:6/23/2017)... ... June 23, 2017 , ... Military Connection friend ... entry to the JFK Virgin Atlantic lounge. , Bensko is no stranger to ... years ago, Bensko dedicated her life to supporting our wounded veterans. A world-class photographer, ...
(Date:6/23/2017)... ... June 23, 2017 , ... Goodcents Deli Fresh Subs ... restaurant is located at 4210 SW 21st St. Topeka, Kan. 66604 (near 21st and ... Graham Restaurant Group who owns three other locations in the Topeka and Bonner Springs, ...
(Date:6/23/2017)... , ... June 23, 2017 , ... ... is essential, and two new videos highlight the importance of correctly using a ... Bruhn, Ph.D., who has done extensive research on consumer food safety habits. Dr. ...
(Date:6/23/2017)... ... ... 21 Middle East and South Asia Leaders Selected as Eisenhower Fellows , ... society in 11 countries across the Middle East and South Asia to embark on ... knowledge and ideas with the leading minds in their fields. , For the ...
(Date:6/23/2017)... ... 23, 2017 , ... PureLife Dental is pleased to announce that California Dental ... As part of the amalgam separator endorsement, all CDA members may purchase an ECO ... the retail value. This partnership between PureLife and CDA is especially timely as it ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... 2017  Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy, ... Iowa location. The ... features an ISO 7 cleanroom—the standard needed to compound intravenous (IV) ... level of pollutants. "Our new ... better serve our Iowa patients," said ...
(Date:6/2/2017)... 2017  NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical technology ... findings demonstrating positive biochemical outcomes related to more frequent ... data will be presented at the ERA-EDTA Congress being ... . The research was conducted ... in Europe (KIHDNEy) Cohort ...
(Date:5/30/2017)... , May 30, 2017 Therapix Biosciences Ltd. ... specializing in the development of cannabinoid-based drugs, today ... company overview at three upcoming scientific and investor ... LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology: